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MicroarrayTGF-ß is protective in atherosclerosis but deleterious in metastatic cancers. Our aim was to determine whether
TGF-ß transcriptional regulation is tissue-speciﬁc in early atherosclerosis. The computational methods included
5 steps: (i) from microarray data of human atherosclerotic carotid tissue, to identify the 10 best co-expressed
genes with TGFB1 (TGFB1 gene cluster), (ii) to choose the 11 proximal promoters, (iii) to predict the TFBS shared
by the promoters, (iv) to identify the common TFs co-expressedwith the TGFB1 gene cluster, and (v) to compare
the common TFs in the early lesions to those identiﬁed in advanced atherosclerotic lesions and in various cancers.
Our results show that EGR1, SP1 and KLF6 could be responsible for TGFB1 basal expression, KLF6 appearing
speciﬁc to atherosclerotic lesions. Among the TFs co-expressed with the gene cluster, transcriptional activators
(SLC2A4RG, MAZ) and repressors (ZBTB7A, PATZ1, ZNF263) could be involved in the ﬁne-tuning of TGFB1
expression in atherosclerosis.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
It is widely accepted that co-expressed genes are likely to share
similar regulatory mechanisms. This hypothesis is the basis for almost
all attempts to usemRNA expression data frommicroarray experiments
to discover regulatory networks [1–4]. Genes with strongly correlated
mRNA expression proﬁles are more likely to have their promoter
regions bound by a common transcription factor (TF). This effect is
present only at relatively high levels of correlation of expression. In
order for two genes to have a greater than 50% chance of sharing a
common TF binder, it has been suggested that the correlation between
their expression proﬁles must be greater than 0.84 [3].
Our study focuses on the transcriptional regulation of the
transforming growth factor-beta (TGF-ß) in human atherosclerosis.
TGF-ß is a ubiquitous cytokine known to have pleiotropic, but context-
dependent, effects on differentiation, proliferation and apoptosis in
physiological as well pathological situations [5] and to play a major role
in the regulation of inﬂammation and immunity [6]. The “protective
cytokine hypothesis” [7,8] attributes to TGF-ß a beneﬁcial role in the
prevention of atherosclerosis on the assumption that TGF-ß plays an
important role in maintaining the normal structure of the vessel wall by
inhibiting vascular smooth muscle cell (vSMC) proliferation and3 Génomique Fonctionnelle de
on Cedex 08, France. Fax: +33migration and by promoting vSMC differentiation. Indeed, long-term
abrogation of TGF-ß signaling aggravated the extent and/or the inﬂam-
matory phenotype of the lesions in atherosclerosis-prone mice [9–12].
Conversely, overexpression of TGF-ß limited plaque growth and stabi-
lized plaque structure in ApoE-deﬁcient mice [13,14]. Taken together,
the available evidence suggests that upregulating TGF-β activity in ath-
erosclerosis is a viable therapeutic option, either to prevent or reduce
atherosclerotic plaque formation, or more likely to induce a transition
from a macrophage-rich unstable plaque phenotype to a more stable,
ﬁbrous lesion [8]. However, due to its ubiquitous expression and pleio-
tropic role, systemic upregulation of TGF-ß activity might be detrimen-
tal. This is exempliﬁed by the dual role of TGF-ß in cancer [15]. Hence,
TGF-ß signaling elicits protective or tumor suppressive effects during
the early growth-sensitive stages of tumorigenesis. However, later in
tumor development when carcinoma cells become refractory to TGF-
ß-mediated growth inhibition, the tumor cell responds by stimulating
pathways with tumor progressing effects. At late stages of malignancy,
tumor progression is driven by TGF-ß overload that induces
epithelial–mesenchymal transition of the tumor cells, neoangiogenesis
and loss of immunosurveillance in the stroma [16].
By far, the vSMCs are the predominant cell type in the arterial wall
and the control of TGF-ß expression in the vSMCs should be pivotal in
the understanding of the protective role exerted by the cytokine in ath-
erosclerosis. The transcriptional control of the TGFB1 promoter has been
the subject of numerous studies [17–32]. However, to our knowledge,
no dedicated study to the transcriptional control of TGF-ß expression
in the vSMCs has ever been published yet.
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control of TGFB1 expression in the vSMCs of human atherosclerotic
carotid samples. Starting frommicroarray transcriptional data obtained
in the laboratory, we selected the genes whose expression was tightly
correlated [33] with that of TGFB1 and analyzed the promoters of
these genes with various bioinformatics approaches to identify
common transcription factor binding sites (TFBS) or transcription factor
cis-regulatory modules. Our analysis shows that, in addition to TFs
and modules already known to be involved in the transcriptional
control of TGFB1, unidentiﬁed TFs might be responsible for the tissue-
speciﬁcity and the ﬁne-tuning of TGFB1 expression in the arterial wall.
2. Results
We studied human carotid endarterectomy samples that were
divided in two parts: the atheroma plaque (ATH) and the nearby
macroscopically intact tissue (MIT). The MIT samples corresponded to
type I or type II lesions [34] with very few foam cells and very limited
extracellular lipid deposits in contrast to type III and IV lesions [34].
The neointima of the MIT contained both myoﬁlament-rich (contrac-
tile) and rough endoplasmic reticulum-rich (synthetic) vSMCs [35]
that produce an abundant extracellular matrix. No vasa vasorum was
observed in the intima of theMIT and the only endothelial cells present
were those lining the lumen of the carotid. Due to the level of the surgi-
cal plane of eversion at endarterectomy, MIT as well as ATH samples
included several layers of media that comprised contractile vSMCs
only. In short, the main cellular contingent in the MIT was, by far,
contractile and synthetic vSMCs. Thus transcriptomic data from MIT
were a reliable reﬂection of gene expression in the vSMCs. Total
mRNA from MIT and ATH paired samples obtained in 32 patients was
analyzed with Affymetrix HuGene 1.0ST microarray. The data have
been deposited in the Gene Expression Omnibus (GEO) public database
(accession GSE43292).
2.1. Expression analysis of TGF-ß isoforms
Expression data obtained from microarrays in 32 patients showed
that the 3 isoforms of the TGF-ß (TGFB1, TGFB2, and TGFB3)were highly
expressed inMIT and ATH: TGFB1 8.51±0.37 inMIT and 8.67± 0.35 in
ATH, TGFB2 8.63 ± 0.56 in MIT and 8.04 ± 0.55 in ATH, and TGFB3
8.11 ± 0.44 in MIT and 7.61 ± 0.40 in ATH (data are mean ± SD,
log2-transformed). All of these valueswere higher than the 70th centile
of the expression value distribution over the whole array. The paired
comparison between ATH and MIT showed that: i) TGFB1 was
signiﬁcantly but weakly over-expressed (expression ratio = 1.12,
local FDR = 0.15%), and ii) TGFB2 and TGFB3 were more widely
under-expressed (expression ratios = 0.66 and 0.71 respectively, local
FDR = 0).
2.2. Genes co-expressed with TGFB1
Fig. 1 gives the comprehensive ﬂowchart of the computational
analyses of expression data and promoter sequences, going back and
forth several times between the results of promoter sequence analyses
and the experimental microarray data.
Numerous transcripts were found highly correlated with the TGFB1
transcript in MIT: 246 with correlation coefﬁcients greater than 0.820
(p b 10−8), reaching maximal value close to 0.95. Results obtained for
TGFB2 and TGFB3 were less signiﬁcant with correlation values lower
than 0.85.
We chose intentionally to focus on the 10 genes whose transcripts
were the most correlated with TGFB1 transcript in the MIT to increase
the chance that they share common TFs. Fig. 2A illustrates the correla-
tions found between the TGFB1 transcript and these10 transcripts,
which ranged between 0.909 and 0.948. These transcripts were not
only correlated with TGFB1 but also highly correlated with each other(mean correlation coefﬁcient at 0.89, clustering coefﬁcient of 0.93 at
p b 10−8). Therefore this set of 11 co-expressed genes was called the
TGFB1 cluster.
Fig. 2B shows that all of these genes were highly expressed. Suppl.
Table 1 gives information about these genes and the functional role of
the encoded proteins. In particular, it is worth noting that the expres-
sions of AKT1 (atheroprotective [36,37] andmodulating TGF-ß signaling
[38–40]), and of ENG and BAG6 (modulators of TGF-ß signaling [41,42])
were correlated with that of TGFB1.
Our approach was based on the double hypothesis that (i) high cor-
relation between two transcripts results from common transcriptional
regulation of the corresponding genes, and (ii) over-representation of
potential transcription factor binding site (TFBS) motifs in a set of co-
expressed gene promoters may indicate common regulation. Therefore
we used the TGFB1 cluster to identify TFs potentially involved in the
TGFB1 transcription in the carotid MIT.2.3. Common TFBS in the promoter sequences of the TGFB1 cluster
Using the Genomatix Software Suite, we ﬁrst identiﬁed 18 TF
families and 32matrices of individual TFs showing TFBS in the proximal
promoter sequences of at least 10 genes of the TGFB1 cluster (Table 1).
Three individual matrices from the Genomatix databasewere excluded:
the V$SP1F/V$GC.01 matrix that did not correspond to a deﬁned TF and
both the V$ZF02/V$ZF9.01 and V$KLFS/V$KLF6.01 matrices. Indeed, al-
though ZF9 is the same TF as KLF6, Genomatix attributed two matrices
to the same TF and these twomatriceswere very dissimilar.Wedecided
to create a new one called U$KLF6 from 20 genomic sequences that had
been experimentally veriﬁed by other authors (see Suppl. data Part 2).
As a result and given that EGR1, SP1 and PLAG1 each had 2 or 3 individ-
ual matrices in the Genomatix database, we identiﬁed the potential
binding of 24 distinct TFs on the 11 promoters of the TGFB1 cluster.2.3.1. Statistical validation
In order to test the robustness of the identiﬁed TFs, we performed a
similar analysis on the promoters of larger sets of genes correlated with
TGFB1, namely 15 and 50 genes. In the ﬁrst case the genes had correla-
tion coefﬁcient higher than 0.907, and in the second case correlation
coefﬁcient was higher than 0.880. The promoter sequence analysis of
the 15 and 50 top correlated genes with TGFB1 in MIT samples shows
that most of the TFs identiﬁed from the 11-gene TGFB1 cluster were
also common to more than 85% of the 15 or 50 top correlated genes
with TGFB1 (Table 2). The very similar results obtained for the 15 top
correlated genes validated the TFs identiﬁed from the 11-gene TGFB1
cluster, except ZNF202. However, PLAG1, ZNF300, ZNF202, SALL2,
ZNF263, GABP, and MZF1 were not detected in the set of 50 genes
correlated with TGFB1. This suggests that genes less correlated with
TGFB1 may share less TFBS.
We analyzed 100 random sets of genes including TGFB1 and 10
genes not co-expressed with TGFB1 to test the hypothesis that the
common TFs obtained fromGenomatix promoter analysis were actually
associated with the co-expression of genes with TGFB1. For each of the
100 random sets, very poor correlation between transcripts was found
(maximummean r value = 0.22). All of the 100 clustering coefﬁcients
were lower than 0.1 at p b 10−8, conﬁrming that the generated random
samples fulﬁlled the null hypothesis of no co-expression.
As shown in the frequency histograms of Fig. 3, themaximumnumber
of individual matrices found present in at least 10 of the 11 promoter
sequences was only 21, and the maximal mean number of TFBS per
selected matrix was 45.2. Because the analysis of our real data identiﬁed
32 individual matrices involving 52.1 TFBS as a mean, we could consider
that the error risk in interpreting the corresponding TFs as potentially
responsible for the co-expression of the 11 genes of the TGFB1 cluster
was very low (b1%).
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Fig. 1. Flowchart of the computational analysis of the transcriptional regulation of TGF-β. The diagram describes the sequence of analyses usingmicroarray data obtained in themacroscopically
intact carotid tissue of atherosclerotic patients (yellow boxes). It indicates the genes or sequences (round corner boxes) obtained from analyses of expression data, DNA sequences, and gene
function, using lab-made co-expression computations, public databases, and Genomatix Software Suite for gene regulation analyses (blue boxes). The simpliﬁed procedure followed for other
atherosclerotic tissues and for cancer tumors is represented in light yellow and purple boxes respectively.MIT:macroscopically intact tissue; TFs: transcription factors; TFBS: transcription factor
binding sites.
359N. Dhaouadi et al. / Genomics 103 (2014) 357–3702.3.2. Properties of the identiﬁed transcription factors in the MIT
These factors were well expressed in the MIT, with KLF6, EGR1, SP1,
GABPA, ZNF148 and CTCF being clearly the 6 most expressed ones with
expression above the 85th percentile of the microarray expression
distribution (Fig. 4A). Among these 6 most expressed TFs, KLF6, EGR1
and SP1 belonged by their expression levels to the top 10% genes out
of all the genes on the microarrays (N90th percentile). Only one TF,
PLAG1, had a rather low expression close to the 25th percentile. Some
of the TFs were strongly correlated with all of the genes of the TGFB1
cluster, especially PATZ1, ZBTB7A, SLC2A4RG, MAZ, and ZNF263 with
high positive correlations (Fig. 4B) (see the TFBS in the TGFB1 promoter
for these 5 factors in Suppl. Fig. 1). However, the most expressed ones,
KLF6, EGR1 and SP1, did not show any correlation with any transcript
of the TGFB1 cluster.2.3.3. Comparison with ATH samples
The implementation of the same analysis on the microarray data
from the ATH samples reveals interesting qualitative and quantitative
differences with the MIT samples.
The 11 genes of the TGFB1 cluster identiﬁed in theMITwere still cor-
related with TGFB1 in the ATH although at a lesser degree (correlation
coefﬁcient between 0.72 and 0.93). Five of the TFs shared by the 11
genes had signiﬁcantly decreased expression in ATH compared to MIT:
ZNF148, SP4, KLF15, SALL2, and ZNF300.
The 10 most tightly correlated genes with TGFB1 in the ATH
diverged from those in the MIT although some of them were common
to both TGFB1 clusters (AKT1, BAG6, and PLXNB2). As a result, the
TFBS identiﬁed on the promoters of the TGFB1 cluster of the ATH were
either shared with the MIT (14 including EGR1, SP1, KLF6, PATZ1,
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Fig. 2. Top 10 correlated transcripts with TGFB1 transcript inmacroscopically intact carotid arterial samples. A. Scatterplots showing the close linear correlation (R) with TGFB1 transcript
across patients; B. Expression of TGFB1 and of the top 10 correlated genes.
360 N. Dhaouadi et al. / Genomics 103 (2014) 357–370SLC2A4RG, ZBTB7A), lost in the ATH (EGR4, GABP, GLIS3, MAZ, SALL2,
WT1, ZNF148, ZNF202, ZNF263, ZNF300) or peculiar to the ATH
(E2F2-3-4, REST, ZBTB14, ZFP57) (Table 3).2.4. Modules of transcription factors
Among the 774 validated transcription modules collected in the
Genomatix MatBase, the ModelInspector tool showed that 3 modules
were present in at least 9 of the 11 promoter sequences of the TGFB1
cluster. These modules associated the SP1 family with either the KLF
or the EGR family, and were denoted KLFS_SP1F_03, EGRF_SP1F_01,
and SP1F_KLFS_01. However, the SP1F_KLFS_01 module was not
found in the TGFB1 promoter sequence.
To go deeper in the analysis, as matrix families comprise related but
different individual matrices, we selected from the module list given by
ModelInspector those involving the individual matrices shared by the
promoters of the TGFB1 cluster, i.e. the individual matrix modules
KLF6_SP1_03, EGR1_SP1_01, and SP1_KLF6_01.
We also investigated whether the module associating SP1 and
KLF6 already identiﬁed in the ENG promoter [43] was found in
other promoters of the genes of the TGFB1 cluster. Analysis with
MatInspector showed that this SP1_KLF6 module was superimpos-
able to the SP1F_KLFS_01 module in MatBase with a slightly weaker
similarity of the KLF6 matrix. This module was named SP1_KLF6_Bo
and was located in the promoters of the TGFB1 cluster, notably in
the TGFB1 promoter. The position and the strand orientation of all
these individual matrix modules in the TGFB1 promoter are in
shown in Suppl. Fig. 1.2.5. Comparison studies with other tissues
Public microarray data from the GEO database obtained in human
atherosclerotic carotid arteries (accession GSE28829 and GSE21545)
were analyzed. In addition, public microarray data obtained in different
types of cancer tumors were analyzed. TGFB1 clusters of highly co-
expressed genes could be identiﬁed in 13 groups of cancer tumors.
The 10 best correlated transcripts with TGFB1 transcript were always
different from those identiﬁed in our data (Suppl. Table 2). This was
not surprising due to the known sampling variability of the correlation
coefﬁcient and to the low number of selected genes.
However, concerning atherosclerotic tissues, the investigation of TFs
having binding sites in at least 10 promoter sequences of the TGFB1 clus-
ter gave more similar results. Table 3 shows that 17 factors were shared
by the TGFB1 clusters identiﬁed in MIT, and in at least one of the athero-
sclerotic tissue sample group. Among them 5 (EGR4, KLF6, SLC2A4RG,
SP4, and ZNF148) were detected in less than 25% of the cancer tumors.
In addition, GABP, GLIS3, SALL2, ZNF202 and ZNF300 were detected
only in carotid MIT and in less than 25% of the cancer tumors, showing
their tissue-speciﬁcity (see results of cancer tumors in Suppl. Table 3).2.6. Concomitant decrease of TGFB1, PLXNB2, AKT1 and ENG expression in
cultured vSMCs following inhibition of SP1 and EGR1 transcriptional
activity
Primary cultures of vSMCs from theMIT of 6 atherosclerotic patients
were used to investigate whether the inhibition of SP1 and EGR1 tran-
scriptional activity was followed by a decrease in the expression of
Table 1
Common matrix families and individual transcription factor matrices in the 11 promoter sequences of the TGFB1 cluster.
Type Family/matrix Current TF symbol # sequences Gene with no match # matches p–value
V$AHRR 10 ENG 22 5.12E–04
V$AP2F – 10 SSRP1 54 2.83E–03
V$CTCF – 11 96 3.41E–04
V$E2FF – 11 100 2.98E–03
V$EGRF – 11 179 7.47E–04
V$ETSF – 11 69 2.84E–02
V$GLIF – 11 51 7.34E–04
V$HDBP – 10 SSRP1 27 1.17E–07
V$KLFS – 11 153 2.27E–02
V$MAZF – 11 87 8.82E–05
V$MZF1 – 10 PLSCR3 43 1.22E–02
V$NDPK – 11 68 1.56E–05
V$PLAG – 11 113 8.43E–04
V$SAL2 – 10 PLXNB2 21 4.72E–05
V$SMAD – 10 BAG6 15 9.80E–03
V$SP1F – 11 141 1.72E–03
V$ZF02 – 11 234 1.95E–03
V$ZF07 – 10 ZC3H7B 37 6.89E–05
U$KLF6 KLF6 11 57 –
V$CTCF/V$CTCF.01 CTCF 11 58 9.23E–08
V$EGRF/V$EGR1.01 EGR1 11 36 1.06E–07
V$EGRF/V$NGFIC.01 EGR4 11 29 4.39E–07
V$EGRF/V$WT1.01 WT1 11 58 1.28E–06
V$ETSF/V$GABP.01 * GABPA–B1–B2 10 FAM65A 21 4.75E–04
V$GLIF/V$GLIS3.01 GLIS3 10 PLSCR3 27 9.46E–06
V$HDBP/V$HDBP1_2.01 SLC2A4RG 10 SSRP1 27 1.17E–07
V$KLFS/V$KKLF.01 KLF15 11 76 5.56E–06
V$KLFS/V$KLF6.01 † KLF6 10 SSRP1 41 3.41E–05
V$MAZF/V$MAZ.01 MAZ 11 51 6.47E–06
V$MAZF/V$MAZR.01 PATZ1 11 78 3.61E–06
V$MZF1/V$MZF1.01 MZF1 10 PLSCR3 35 5.64E–04
V$NDPK/V$NM23.01 NME1 11 77 1.56E–05
V$PLAG/V$PLAG1.01 PLAG1 11 62 1.04E–06
V$SAL2/V$SALL2.01 SALL2 10 PLXNB2 21 4.72E–05
V$SP1F/V$GC.01 no 11 86 8.67E–06
V$SP1F/V$SP1.01 SP1 11 89 4.63E–06
V$SP1F/V$SP2.01 SP2 11 31 8.66E–07
V$SP1F/V$SP4.01 SP4 10 ENG 48 7.21E–06
V$ZF02/V$ZBP89.01 ZNF148 11 75 1.64E–06
V$ZF02/V$ZBTB7.03 ZBTB7A 11 88 1.84E–05
V$ZF02/V$ZF9.01 † KLF6/ZF9 11 65 1.69E–06
V$ZF02/V$ZNF202.01 ZNF202 10 PLSCR3 24 7.21E–06
V$ZF02/V$ZNF219.01 ZNF219 11 90 2.22E–06
V$ZF02/V$ZNF300.01 ZNF300 10 PLSCR3 22 1.55E–06
V$ZF07/V$ZNF263.01 ZNF263 10 ZC3H7B 37 6.89E–05
Individual 
matrix
Matrix 
family
U$: user-deﬁned matrix; V$: vertebrate matrix; TF: transcription factor.
Gray background: transcription factor matrix detected in all of the 11 sequences.
In bold, the matrix families including at least one transcription factor with enriched binding sites.
The individual matrices matching 10/11 promoters match the TGFB1 promoter.
The p-values are only correct if sequences with an average length of about 600 basepairs are searched for TF sites with optimized matrix similarity.
*: the GABP transcription factor includes 3 subunits alpha, beta 1, and beta 2, each encoded by a speciﬁc gene.
†: after veriﬁcation these matrices were not considered, and replaced by U$KLF6; no: no TF associated with the matrix.
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ter, i.e. PLXNB2, AKT1 and ENG. Expression levels were measured by
quantitative RT-PCR. Mithramycin A directly blocks the binding of SP1by competing with GC-rich sequences in the promoters and blocks
SP1 activity [44]. As EGR1 activation by phosphorylation is highly de-
pendent on vSMCs upon PKC-ß activity, inhibitors of PKC-ß have been
Table 2
Individual transcription factor matrices common to promoter sequences of different sets of genes co-expressed with TGFB1 in the carotid macroscopically intact tissue.
Current TF
symbol
Family/Matrix Number
of times
TGFB1 + 10best correlated genes TGFB1 + 15 best correlated genes TGFB1 + 50 best correlated genes
#seq/11
(N=10 = 91%)
p-value #seq/16
(N=14 = 87.5%)
p-value #seq/51
(N=44 = 86%)
p-value
KLF6 U$KLF6 3 11 – 16 – 50 –
KLF15 V$KLFS/V$KKLF.01 3 11 5.56E−06 16 2.76E−08 50 3.03E−22
CTCF V$CTCF/V$CTCF.01 3 11 9.23E−08 16 6.62E−11 49 1.15E−28
SP1 V$SP1F/V$SP1.01 3 11 4.63E−06 16 2.10E−08 49 6.25E−21
ZBTB7A V$ZF02/V$ZBTB7.03 3 11 1.84E−05 16 1.61E−07 49 3.49E−18
EGR1 V$EGRF/V$EGR1.03 3 11 1.08E−06 16 2.44E−09 48 3.12E−22
NME1 V$NDPK/V$NM23.01 3 11 1.56E−05 16 1.27E−07 48 4.44E−17
PLAG1 V$PLAG/V$PLAG1.01 3 11 1.04E−06 16 2.32E−09 48 2.67E−22
ZNF219 V$ZF02/V$ZNF219.01 3 11 2.22E−06 16 7.10E−09 47 2.01E−19
EGR4 V$EGRF/V$NGFIC.01 3 11 4.39E−07 16 6.53E−10 46 4.89E−21
ZNF148 V$ZF02/V$ZBP89.01 3 11 1.64E−06 16 4.54E−09 44 2.96E−16
SP2 V$SP1F/V$SP2.01 3 11 8.66E−07 15 1.01E−07 45 1.56E−18
WT1 V$EGRF/V$WT1.01 3 11 1.28E−06 15 1.73E−07 44 1.15E−16
MAZ V$MAZF/V$MAZ.01 3 11 6.47E−06 15 1.62E−06 44 6.03E−14
PATZ1 V$MAZF/V$MAZR.01 3 11 3.61E−06 14 1.13E−05 44 6.33E−15
SP4 V$SP1F/V$SP4.01 3 10 7.21E−06 15 9.55E−09 46 6.83E−23
SLC2A4RG V$HDBP/V$HDBP1_2.01 3 10 1.17E−07 15 1.88E−11 45 1.71E−29
GABPA-B1-2 V$ETSF/V$GABP.01 2 10 4.75E−04 14 7.01E−05
GLIS3 V$GLIF/V$GLIS3.01 2 10 9.46E−06 14 3.25E−07
MZF1 V$MZF1/V$MZF1.01 2 10 5.64E−04 14 8.86E−05
SALL2 V$SAL2/V$SALL2.01 2 10 4.72E−05 14 2.98E−06
ZNF300 V$ZF02/V$ZNF300.01 2 10 1.55E−06 14 2.68E−08
ZNF263 V$ZF07/V$ZNF263.01 2 10 6.89E−05 14 5.00E−06
E2F4 V$E2FF/V$E2F4.01 2 14 4.52E−09 46 1.69E−28
ZNF202 V$ZF02/V$ZNF202.01 1 10 7.21E−06
TFAP2B V$AP2F/V$TCFAP2B.01 1 14 6.38E−08
TF: transcription factor.
362 N. Dhaouadi et al. / Genomics 103 (2014) 357–370shown to decrease EGR1 transcriptional activity in this cell type [45].
Figs. 5A and 5B show that mithramycin A and the PKC-ß inhibitor ad-
ministered separately signiﬁcantly decreased TGFB1, PLXNB2, AKT1
and ENG expression in a dose-dependent manner. Combination of the
two inhibitors had a cumulative effect on the percentage of inhibition
(Fig. 5C). In addition, in each of the 6 patients, TGFB1 expression values
were highly correlated with those of PLXNB2, AKT1 and ENG across
the 4 pharmacological conditions using either mithramycin A or PKC-
ß inhibitor (mean correlation coefﬁcients ranging between 0.877,
p = 0.12, and 0.969, p = 0.03) (see Suppl. Fig. 2).3. Discussion
3.1. Summary of results
In this work, we used microarray data and gene co-expression anal-
ysis to investigate the transcriptional regulation of TGF-ß, represented
by the TGFB1 gene coding for the isoform 1, speciﬁcally in early lesions
(MIT) of atherosclerotic human carotid arteries.
We identiﬁed 24 TFs potentially involved in the transcriptional reg-
ulation of TGFB1 in the MIT. Among the most expressed ones, KLF6,
EGR1 and SP1 stand out by (i) their high level of expression in the
sample, and (ii) the fact that their involvement in the transcriptional
regulation of TGFB1 had been experimentally veriﬁed in various cell
types or tissues [17,18,22,23,25,28]. This suggests that these 3 TFs may
be at the core of the constitutive transcriptional regulation of the ubiq-
uitous TGFB1 gene. The remaining 21 TFs have never been related to the
regulation of TGFB1 expression. Three of them (PATZ1, ZBTB7A, and
SLC2A4RG) distinguish themselves by (i) their strong co-expression
with the TGFB1 gene cluster, and (ii) their robust conservation among
the different atherosclerotic tissues we analyzed. We propose that
these 3 co-regulated TFs might be responsible for the ﬁne-tuning of
the tissue-speciﬁc TGFB1 expression in the vSMCs in atherosclerotic
lesions. Among them, SLC2A4RG is of particular interest since it
appeared rarely involved in the TGFB1 regulation in cancer.3.2. Speciﬁcities of the methodological approach
3.2.1. Choice of the samples
The work focused on the carotid MIT to restrict the study of the
transcriptional control of TGFB1 expression in the vSMCs of the
human atherosclerotic carotid artery with the least possible interfer-
ence of the inﬂammatory inﬁltrate and endothelium lining the
neovessels. In the MIT, the vSMCs form, indeed, the overwhelming
majority of the cells. However, medial and intimal vSMCs may present
phenotypic differences. For instance, it was reported that intimal vSMCs
express EGR1 at a higher level than their medial counterparts [46].
3.2.2. Inter-individual variation
In this work, co-expression has been exploited to ﬁnd novel candi-
date genes correlated with TGFB1 that presents a particular interest in
atherosclerosis. The source of variability of gene expression used to
compute the correlation of gene pairs was the inter-individual variation
between patients suffering atherosclerotic lesions of the carotid artery.
This inter-individual variability produced a rather limited range of ex-
pression variation (1.9 to 3-fold for the 11 genes) that was, however,
wide enough to allow the robust estimation of correlation coefﬁcients.
3.2.3. Determination of the promoter sequences
We studied proximal promoter sequences because it has been deter-
mined that functional TFBS tend to bemore conserved and located clos-
er to the transcription starting site (TSS) than predicted binding sites
whose functional impact on promoter activity was not detected [47].
Remarkably, the 11 promoters of the genes in the TGFB1 cluster in the
MIT samples belonged to the group of promoters with high CpG content
that are known to harbor multiple and scattered TSS [48]. Taking into
account these functional and structural constraints led us to design,
for certain genes, several putative proximal promoter sequences around
potential upstream TSS out of which the one sharing the most numer-
ous TFBS with the TGFB1 promoter sequence was eventually selected.
Interestingly, all the selected promoter sequences encompass the
Number of TF matrices
Fr
eq
ue
nc
y
real data: 
32
Mean numberof  TFBS
per TF matrix    
real data: 
52.1
Fr
eq
ue
nc
y
A
B
0 5 10 15 20 25 30 35
0 10 20 30 40 50 60
0
10
20
30
40
50
60
0
10
20
30
40
Fig. 3. Transcription factors (TF) common to the genes of random 11-gene sets including
TGFB1. The ﬁgure shows the frequency histograms of the numbers of: A. transcription
factor (TF) positionweightmatrices, and B. TF binding sites (TFBS) per TFmatrix common
to at least 10 genes of the gene sets. One hundred random gene sets were generated from
the genes uncorrelated with TGFB1 in macroscopically intact carotid samples, and includ-
ed TGFB1. The result obtained from real data is indicated on each histogram.
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NCBI database.
3.2.4. Bioinformatics
The selection of genes highly co-expressed with TGFB1 in the carotid
MIT acted as aﬁlter to obtain TFs potentially involved in the transcription-
al regulation of TGFB1 that could be speciﬁc of low-grade atherosclerotic
lesions.
Although the molecular mechanisms underpinning co-expression
are not fully understood, it has long been accepted that co-expressed
genes are likely to share transcriptional regulation as shown in model
organisms or mammals [1–4,49]. In addition, the number of common
TFBS has been shown to increase as the co-expression correlation be-
tween two genes [4]. Moreover, co-expression correlations between
TFs and their target genes have also been shown initially in lower eu-
karyotes [50] and then in mammals [4]. In humans, several approaches
have been proposed for the inference of interactions between TFs and
their targets [51]. They have been applied to various cell types [52,53]
or pathological tissues [49,54] identifying new TFs of interest.
Although our approach remains within this general conceptual frame,
we used it in speciﬁc ways. Firstly, instead of enlarging the number of
genes co-expressed with TGFB1 to build a functional regulatory network
around it, we restricted this number to the 10 most co-expressed ones tocharacterize precisely the TFs involved in the regulation of TGFB1 expres-
sion in the vSMCs of atherosclerotic lesions. Secondly, we paid a peculiar
attention to the TFs that were co-expressed with the 11 genes of the
TGFB1 cluster hypothesizing that these co-expressed TFs might be in-
volved in the ﬁne-tuning of TGFB1 expression in the vSMCs through
short regulatory loops. Of course, the absence of correlation does not
necessarily result from the absence of any transcriptional activity of the
factor. It may arise from (i) substantial difference between the mRNA
and the activated protein levels of the TF, or (ii) too small range of gene
expression variation across quite homogeneous samples. This latter
point is of special importance for highly expressed genes whose correla-
tions with potential TFs mostly reﬂect ﬁne-tuning of basal expression
level. This level should be controlled by other TFs that appear uncorrelat-
ed with their targets.
It is known that positionweightmatrix (PWM)-basedmethodsmay
generate false positive predictions. The Genomatix results of over-
representation of TFBS for individual matrices in the TGFB1 cluster
could have been obtained by chance, but the comparison with sets of
non-correlated genes including TGFB1 showed that our results were
statistically signiﬁcant. In addition, the identiﬁed individual matrices
were robust since similar ones were detected with 15 genes co-
expressed with TGFB1. Increasing the number of genes co-expressed
with TGFB1 tended to decrease the similarity. This can be explained
by the fact the co-expression ﬁlter was less stringent when considering
50 genes, and that the hypothesis of common transcriptional regulation
was less borne out.
3.2.5. Preliminary experimental validation of the computational results
We chose to study in cultured human vSMCs the control, by SP1 and
EGR1, of the expression of TGFB1—the main focus of our study—,
PLXNB2—the most tightly co-expressed gene in the TGFB1 cluster—,
AKT1—the second atheroprotective gene of the cluster [36,37]—, and
ENG—a gene already known to be co-regulated with TGFB1 by SP1
[43]. Inhibition of the activity of SP1 and EGR1 induced a comparable
decrease in the expression of all four genes. On the one hand, these pre-
liminary experimental results show that our major working hypothesis
that co-expressed genes are likely to share similar regulatory
mechanisms is correct because at least four genes of the TGFB1 co-
expression cluster were co-regulated in response to two independent
pharmacological challenges. On the other, these results functionally
strengthen the validity of the bioinformatics prediction of SP1 and
EGR1 binding sites in the promoter sequences of the four genes, and in-
crease the likeliness that other TFBS predicted by the same method
could be functional. Much work, however, remains to be done to fully
demonstrate that all of the genes of the TGFB1 cluster are actually regu-
lated by the occupancy of TFBS predicted by the bioinformatics tools.
3.3. Functional interpretation of the results
We are conscious of the caveats of the functional interpretation of
the analysis of transcriptomic microarray data with bioinformatics
tools: transcript levels are not synonymouswith protein levels; proteins
undergo many post-translational modiﬁcations that modulate their
activities; TFs through protein–protein interactions may have versatile
effects on transcription; false positive predictions may result from the
PWM-based methods. However, the validation of our methodological
approach (see above) and the cross-checking of our bioinformatics
results with experimental data from the literature allowed us to pro-
pose new candidate TFs involved in the regulation of TGFB1 expression
in the vSMCs of the atherosclerotic human carotid artery.
3.3.1. The TGFB1 cluster in carotid MIT
Interestingly, functional relationships between the proteins encoded
by the TGFB1 gene and some of the correlated genes have been report-
ed. Just as TGF-ß1 that is considered a protective cytokine, the activity of
the serine–threonine protein kinase encoded by the AKT1 gene has
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364 N. Dhaouadi et al. / Genomics 103 (2014) 357–370been shown to oppose the development of atherosclerosis in mice [36,
37]. The proteins encoded by ENG, an auxiliary receptor for several
members of the TGF-ß superfamily [41], BAG6 [42] and AKT1 [38–40]
interact at various levels with the TGF-ß signaling pathway. This
means that even a very small cluster of genes that co-regulated with
TGFB1 contains genes related to its functions.
Surprisingly, the TGFB1 clusters identiﬁed in our MIT samples and
other atherosclerotic carotid samples were quite different. This variabil-
ity results from the low number of selected genes combined to the
known sampling variability of the correlation coefﬁcient in samples of
small size [55]. However, despite the variability of the genes in these
different atherosclerotic TGFB1 clusters, the TFBS shared by their
promoters displayed a much stronger conservation.
3.3.2. The MIT vs. other atherosclerotic samples
If fourteen of the TFs detected in MIT were also found in the athero-
ma plaque, thirteen were common to at least 3 types of atherosclerotic
carotid samples (CTCF, EGR1, KLF15, KLF6, NME1, PATZ1, PLAG1,
SLC2A4RG, SP1-2-4, ZBTB7A, and ZNF219). They were obtained from
clusters of different genes highly co-expressed with TGFB1, showing
that despite their heterogeneity these genes shared potential transcrip-
tional regulators by virtue of their co-expressionwith TGFB1. This resultshows the robustness of their identiﬁcation across various stages of ath-
eroma development associated with the evolving cellular composition
of the lesions. These TFs may be related to the transcription of TGFB1
in early or advanced stages of pathological vascular remodeling.
The differences with the dataset GSE28829 may come, as stated
above, from sampling variability of the correlation coefﬁcient in samples
of small size (n= 13 and 16 for the two groups in this dataset) [55] but
also from the fact that the carotid samples were obtained at autopsy al-
though the authors have shown that the expression level of more than
97% of the genes were not affected whether the tissues were obtained
at surgery or autopsy [56].
3.3.3. Transcriptional regulation of TGFB1 in the vSMCs in atherosclerosis
The 24 TFs identiﬁed by our study and potentially involved in the
transcriptional regulation of TGFB1 in the MIT can be subdivided into
4 groups according to (i) their association with the grade of the athero-
sclerotic lesions (MIT, early or advanced lesions), and (ii) their possible
involvement in TGFB1 expression in the 13 cancer datasets.
Group 1 includes SP1, NME1, ZBTB7A, PATZ1, SP2, EGR1, CTCF,
PLAG1, ZNF219, KLF15, MZF1 and WT1. As these TFs were found in N3
groups of atherosclerotic lesions of all grades including MIT and in N3
cancer groups, we consider that they may impact TGFB1 expression all
Table 3
Individual matrices corresponding to TFBS in at least 10 genes of the TGFB1 cluster in human carotid atherosclerotic lesions at different stages.
GSE21545
MIT Atheroma 
plaque
Early 
lesion
Advanced 
lesion
Atheroma 
plaque
CTCF V$CTCF/V$CTCF.01-04 x x x x x
EGR1 V$EGRF/V$EGR1.01-03 x x x x x
NME1 V$NDPK/V$NM23.01 x x x x x
PATZ1 V$MAZF/V$MAZR.01 x x x x x
SP1 V$SP1F/V$SP1.01 x x x x x
SP2 V$SP1F/V$SP2.01 x x x x x
ZBTB7A V$ZF02/V$ZBTB7.03 x x x x x
PLAG1 V$PLAG/V$PLAG1.01 x x x x
ZNF219 V$ZF02/V$ZNF219.01 x x x
KLF15 V$KLFS/V$KKLF.01 x x x
MZF1 V$MZF1/V$MZF1.01 x x
WT1 V$EGRF/V$WT1.01 x x
SP4 V$SP1F/V$SP4.01 x x x x x
KLF6 U$KLF6 x x x x
SLC2A4RG V$HDBP/V$HDBP1_2.01 x x x
EGR4 V$EGRF/V$NGFIC.01 x x
ZNF148 V$ZF02/V$ZBP89.01 x x
MAZ V$MAZF/V$MAZ.01 x
ZNF263 V$ZF07/V$ZNF263.01 x
GABPA-B1-2 V$ETSF/V$GABP.01 x
GLIS3 V$GLIF/V$GLIS3.01 x
SALL2 V$SAL2/V$SALL2.01 x
ZNF202 V$ZF02/V$ZNF202.01 x
ZNF300 V$ZF02/V$ZNF300.01 x
E2F4 V$E2FF/V$E2F4.01 x x x
REST V$NRSF/V$NRSE.01 x x
ZBTB14 V$ZF5F/V$ZF5.03 x x
Present in several 
advanced carotid 
atheroma groups
GSE28829Tissue specificity Current TF 
symbol
Family/matrix GSE43292
Common to several 
carotid tissue 
groups, and often 
detected in cancer 
tumors
Only in carotid MIT, 
but often detected 
in cancer tumors
Fully specific to 
carotid MIT
Common to several 
carotid tissue 
groups, and rarely 
detected in cancer 
tumors
In bold with gray background, transcription factors speciﬁc of the carotid tissue.
TF: transcription factor; MIT: macroscopically intact tissue;
365N. Dhaouadi et al. / Genomics 103 (2014) 357–370along lesion development but not in a vSMC-speciﬁc fashion. Among
the TFs in Group 1, EGR1 and SP1 were highly expressed in the MIT.
They have been shown to strongly stimulate TGFB1 expression in vari-
ous non-vascular cell types, and are considered asmajor transcriptional
activators of the expression of the gene [18,23–25,28,57]. Our results on
cultured vSMCs strongly suggest that such is the case in human vSMCs.
These experimental data, and the fact that EGR1 and SP1 seemed to be
involved in the regulation of TGFB1 in most of the cancer groups that
we analyzed, strongly suggest that these two TFs are involved in the
constitutive expression of the TGFB1 gene in most tissues including
the human vSMCs. This is also supported by the fact that the expression
levels of EGR1 and SP1 are not correlated with those of the genes of
the TGFB1 cluster in the MIT. However, as our study relies only on
transcriptomic data, further work is needed to investigate whether the
variations of TGFB1 expression in the MIT sample simply reﬂects the
variations of EGR1 and SP1 protein levels and/ormodulation of their ac-
tivities through post-translational modiﬁcations [58,59]. On the other
hand, WT1 has been shown to efﬁciently repress the basal of EGR1-
stimulated expression of TGFB1 [22,60]. Another TF in Group 1, SP2,
might have functions similar to those of SP1 [61]. Three TFs in this
group (NME1, CTCF and PLAG1) have been linked to the TGF-ß signalingpathway. NME1 is induced by TGF-ß1 [62]. It inhibits TGF-ß-induced
epithelial to mesenchymal transition [63] as well as apoptosis and
growth inhibition [64]. Smad 3, signaling downstream of TGF-ß, inter-
acts with CTCF in the control of the imprinting control region of the
H19 gene [65]. PLAG1 is upregulated by TGF-ß in cancer cells [62].
Two other TFs in this group (PATZ1 and KLF15) are related to athero-
sclerosis or the vSMCs. PATZ1, shown to inhibit endothelial cell senes-
cence, is expressed at a lower level in the endothelium and vSMCs of
atherosclerotic tissues [66]. KLF15 has been identiﬁed as an inhibitor
of vSMC proliferation and migration, and implicated as a critical regula-
tor of the vascular response to injury [67]. Indeed, invalidation of Klf15
in mice leads to both heart failure and aortic aneurysm formation [68].
The 3 last TFs in this group (ZBTB7A, ZNF219 and MZF1) have not
been reported to be associated with TGFB1 expression or atherosclero-
sis. ZBTB7A [69] and ZNF219 [70] are considered as transcriptional
repressors. Surprisingly, ZBTB7A and PATZ1 are the 2 TFs in Group 1 to
be co-expressed with the 11 genes of the TGFB1 cluster in the MIT.
Since the 12 TFs in Group 1 have over-represented TFBS in the
promoters of the TGFB1 gene clusters of more than 3 cancer datasets,
they are not good candidates for the control of cell-speciﬁc expression
of TGFB1 in vSMCs.
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Fig. 5. Regulation of the expression of four genes of the TGFB1 cluster by SP1 and EGR1 in
human cultured vSMCs from the MIT of 6 patients. A and B. Cells were treated for 24 h
with increasing concentrations (50, 100 and200nM)ofmithramycinA (MTM), a SP1 inhib-
itor (A) or PKC-ß inhibitor (PKCi), inhibitor of EGR1 activation (B). Total RNAwas extracted
and TGFB1, PLXNB2, AKT1 and ENGmRNA levels weremeasured by quantitative RT-PCR. C.
Effect of the simultaneous treatment of vSMCswith MTM and PKCi at 100 or 200 nM each.
Each experiment was run in duplicate. Values in control wells were taken as 100%. Results
are expressed as mean ± SEM. Control (CTRL) vs. treated cells: + p b 0.05, x p b0.01,
* p b 0.001.
366 N. Dhaouadi et al. / Genomics 103 (2014) 357–370Group 2 includes SP4, KLF6, SLC2A4RG, EGR4 and ZNF148. As these
TFs were found in N3 groups of atherosclerotic lesions of all grades in-
cludingMIT and in≤3 cancer groups,we consider that theymay impact
TGFB1 expression all along lesion development in a vSMC-speciﬁc fash-
ion. InGroup 2, KLF6 stands out by its very high level of expression in the
MIT. KLF6 and SP1 have been shown to cooperate in the expression of
TGFB1 in hepatic stellate cells [25]. Interestingly, in vascular endothelial
cells the same cooperative interaction between SP1 and KLF6 was
shown to activate the expression of TGFB1 and ENG [43], 2 genes of
the TGFB1 cluster in the MIT. On the whole, the cooperative interaction
between KLF6 and SP1 was found in the promoters of 8 out of 11 genes
of the TGFB1 cluster of the MIT. The functionality of the SP1_KLF6_Bomodule has been experimentally veriﬁed on the ENG promoter [43].
KLF6 TFBS were over-represented in the promoters of the TGFB1
clusters in all groups of atherosclerotic samples but in less than 25% of
the groups of cancer samples, while EGR1 and SP1 TFBS were over-
represented in all groups of atherosclerotic samples and frequently in
cancer groups. This suggests that KLF6, in contrast to SP1 and EGR1 in
Group 1, represents a vSMC-speciﬁc transcriptional activator of TGFB1
expression in atherosclerotic lesions of all grades. Similarly to EGR1
and SP1, the expression levels of KLF6 were not correlated with those
of the TGFB1 gene cluster in the MIT. In comparison with EGR1 and
SP1, we propose that KLF6 is implicated in the constitutive, but vSMC-
speciﬁc, expression of TGFB1. However, the KLF6 protein is the target
of post-translational modiﬁcations that modulate its transcriptional ac-
tivity [71]. Moreover, the proteins encoded by the splice variants of the
KLF6 gene have a dominant negative impact on the transcriptional ac-
tivity of the full-length KLF6 protein [72]. Analysis of the hybridization
of the individual Affymetrix exonic probes for the KLF6 gene did not
allow us to determine whether these splice variants were expressed in
the MIT samples (data not shown). Interestingly, according to the cell
type, TGF-β1 may decrease KLF6 alternative splicing, resulting in a net
increase in full-length KLF6 activity [72].
SLC2A4RG is implicated in the expression of the glucose trans-
porter 4 (GLUT4) [73], whose expression is regulated by hypoxia
[74]. In atherosclerosis, the thickening of the avascular arterial wall
results in hypoxia in the lesions so that hypoxia-driven genes like
the glucose transporters are highly expressed [56,75]. Our results
suggest that SLC2A4RGmight take part in both themetabolic adapta-
tion to hypoxic conditions and the regulation of TGFB1 in atheroscle-
rotic lesions of all grades. This transcriptional control seems to be
speciﬁc to the vSMCs as SLC2A4RG TFBS were identiﬁed in one
group of cancers only, leiomyosarcoma that is a cancer of smooth
muscle. Moreover, in the MIT, SLC2A4RG expression levels were
positively correlated with those of the genes of the TGFB1 cluster.
This strongly suggests that SLC2A4RG might be implicated in the
ﬁne-tuning of TGFB1 expression in atherosclerosis. Other TFs in
Group 2 include SP4 and EGR4 that are structurally and functionally
related to SP1 and EGR1 (see above). The last member of Group 2 is
the transcriptional repressor ZNF148 that has never been linked to
TGFB1 expression or atherosclerosis.
Group 3 comprises a unique TF, E2F4, that was found in 3 groups of
advanced atherosclerotic lesions and in N3 cancer groups. Therefore, it
may impact TGFB1 expression only in advanced atherosclerotic lesions
but not in a vSMC-speciﬁc fashion. It belongs to the E2F family themem-
bers of which have important roles in cell cycle progression. A ChIP-seq
study has shown that 5 genes of the TGFB1 co-expression cluster
(TGFB1, USP22, PLSCR3, SSRP1 and ZC3H7B) are putative E2F4 target
genes [76]. E2F family members interact with the TGF-ß signaling path-
way by forming complexes with Smad 3 to regulate the expression of
the MYC gene [77]. E2F3 promotes proliferation of vSMCs leading to
increased intimal hyperplasia, whereas E2F4 inhibits this pathological
response in mice [78]. In all groups of advanced lesions, E2F4 TFBS
were common to the promoters of the TGFB1 cluster while E2F3 TFBS
were found only in our ATH samples (data not shown). This suggests
that a shift of TGFB1 transcriptional control from E2F3 to E2F4 might
be linked to an inhibitory response to vSMC proliferation as lesions
advance.
Group 4 includes REST and ZBTB14. As these TFs were found in 2
groups of advanced atherosclerotic lesions and in ≤3 cancer groups,
they may impact TGFB1 expression only in advanced atherosclerotic le-
sions in a vSMC-speciﬁc fashion. They are two recognized transcription-
al repressors of which REST only has been linked to intimal hyperplasia
and atherosclerosis. It enhances vSMCproliferation andmigration by in-
ducing a shift in the types of ion channel controlling trans-membrane
ion transport [79].
In addition to these 4 groups of TFs identiﬁed in atherosclerotic
lesions at different stages, 2 additional groups, only associated with
367N. Dhaouadi et al. / Genomics 103 (2014) 357–370MIT, deserve interest. Group 5 includes MAZ and ZNF263. As these TFs
were found in the MIT only and in N3 cancer groups, we consider that
they may impact TGFB1 expression only in early atherosclerotic lesions
but not in a vSMC-speciﬁc fashion. Binding of SAF-1, an isoform of MAZ,
to theMMP-14 promoter up-regulates the transcription of theMMP-14
gene in the macrophages of atherosclerotic lesions [80]. Themembrane
bound MMP14 has been shown to shed the ectodomain of endoglin to
generate soluble endoglin that is known as an anti-angiogenic factor
[81]. MAZ induces thrombospondin 1 expression in pulmonary artery
vascular cells [82]. As thrombospondin 1 plays a key role in thematura-
tion process of the latent forms of TGF-ß1, its upregulation by MAZ
could increase the bioavailability of the active TGF-ß protein in the pul-
monary artery wall [82]. Taken together, MAZ could not only induce
TGFB1 expression in the MIT but also increase the amount of active
TGF-ß and inhibit neovascularization in early lesions. Concerning
ZNF263, 5 genes of the TGFB1 co-expression cluster (TGFB1, EML3,
BAG6, ZC3H7B and FAM65A) are putative genomic targets of this
KRAB and SCANdomain-containing zincﬁnger protein [83]. The expres-
sion levels of both MAZ and ZNF263 were correlated with those of the
TGFB1 gene cluster in the MIT.
Group 6 comprises GABP, GLIS3, SALL2, ZNF202 and ZNF300. As
these TFs were found in the MIT only and in ≤3 cancer groups, we
consider that they may impact TGFB1 expression only in early ath-
erosclerotic lesions in a vSMC-speciﬁc fashion. No reports link
GLIS3 or the transcriptional repressor ZNF300 to either the TGF-ß
signaling pathway or atherosclerosis. However, GLI2, a TF very close-
ly related to GLIS3, has been shown to potently induce TGFB1 expres-
sion in CD4+ T cells [32]. GABP is a multimeric TF that belongs to the
Ets family. The GABPA encodes the DNA-binding monomer, and
GABPB1 and 2 the monomers responsible for transactivation. In
mouse B-cell lines, mouse mammary tumor virus transcription re-
quires the cooperation of GABPwith both the glucocorticoid receptor
and the TGF-ß-activated Smads [84]. In response to serum, GABP
binding activates the promoter of the serine/threonine protein
kinase UHMK1 that promotes cell cycle progression through G1,
leading to UHMK1 gene expression, cell migration, and cell cycle
progression in cultured vSMCs [85]. The expression of SALL2 in ﬁbro-
blasts is inhibited by TGF-ß [86]. The zinc ﬁnger protein ZNF202 is a
transcriptional suppressor of apolipoprotein related genes [87]. In
vivo ZNF202 overexpression in mice induces hepatosteatosis and a
sharp decrease in the atheroprotective HDL cholesterol levels [87].
In line with this, homozygosity for a common variant in the
ZNF202 promoter in humans predicts severe atherosclerosis and an
increased risk of ischemic heart disease [88]. Increased ZNF202 ex-
pression might thus play a deleterious role in the evolution of early
atherosclerotic lesions.
To conclude, agreement between experimentally veriﬁed data and
the results of our computational analysis of microarray expression
datasets provides soundness to our approach dedicated to a better un-
derstanding of TGFB1 expression in the vSMCs during atherosclerosis.
The merit of our work is to attribute to TFs already experimentally
shown to regulate TGFB1 expression their speciﬁc involvement in the
vSMCs (KLF6), to propose new putative vSMC-speciﬁc TFs (SLC2A4RG,
GABP and SALL2) that may favor the atheroprotective role of TGFB1
by promoting its expression at different stages of atherosclerosis, and
to identify at least one TF (ZNF202) the over-expression of which
could have adverse effects.
Provided thatmost of the putative TFs identiﬁed here are actually in-
volved in the transcriptional regulation of TGFB1 in the vSMCs, more
than 20 TFs regulate the same gene cluster. This is a characteristic for
complex robust systems, in which robustness is ensured bymultiple in-
puts. However, out of the ﬁve TFs co-expressed with the TGFB1 cluster
(ZBTB7A, PATZ1, SLC2A4RG, MAZ and ZNF263), three are considered
as transcriptional repressors (ZBTB7A, PATZ1 and ZNF263). Such
opposite functions of the TFs co-expressed with TGFB1 suggest that
TGFB1 expression in the vSMCs could follow an oscillatory pattern ofchange in time. These salient computational results need of course
experimental conﬁrmation.
4. Material and methods
4.1. Patients and endarterectomy pieces
The investigation conforms to the principles outlined in the declara-
tion of Helsinki, all procedures were approved by the local ethical com-
mittee and the patients gave informed consent [89]. Forty-three
hypertensive patients who underwent carotid endarterectomy at the
University Hospital of Lyon (Department of Vascular Surgery, Hospital
Edouard Herriot, Lyon, France) were included in the study. The carotid
endarterectomy sampleswere collected in the surgery room and imme-
diately dissected in two fragments: the atheroma plaque (ATH) and the
nearby macroscopically intact tissue (MIT). Each fragment was further
divided: one part was immediately frozen in liquid nitrogen for RNA
and protein analysis, whereas the other was used for histological
examination.
4.2. Microarray analysis
Total mRNA from MIT and ATH paired samples obtained in 32 pa-
tients was analyzed with Affymetrix HuGene 1.0ST microarray includ-
ing 28,869 probe sets targeting human genes. Data were normalized
with Affymetrix Expression Console software using the RMA method
and were log2-transformed. No expression threshold was imposed,
but expression of genes emerging from our computations was checked,
bearing interest only at genes with mean expression higher than the
25th percentile of expression distribution over the whole array (log2
expression N4.45).
The comparison of expression values between ATH and MIT was
made by a speciﬁc method (Signiﬁcance Analysis of Microarray, SAM,
R package samr) using a modiﬁed t-test and correction for multiple
comparisons that gave local false discovery rate (FDR) as error risk.
The signiﬁcance threshold was taken at local FDR b 5%.
4.3. Computational analyses
4.3.1. Gene co-expression
Gene co-expression was investigated from the computation of the
Pearson correlation coefﬁcient between expression values of one gene
of interest and of the other genes present on the microarray across a
group of individual samples. The top 10 genes most correlated with
the geneof interestwere selected, and the internal pairwise correlations
within this set of genes were tested. The correlation threshold was
taken at 0.7, ensuring signiﬁcance between p b 0.0077 and p b 10−10
for n ranging between 13 and 126. High internal correlations leading
to high clustering coefﬁcient (ratio of the number of signiﬁcant correla-
tions to the total number of gene pairs) allowed deﬁning an 11-gene
cluster of co-expressed genes.
4.3.2. Determinants of gene co-expression: bioinformatics approach
We analyzed the transcriptional regulation of the co-expressed
genes with a computational approach, examining the presence of com-
mon TFBS and their association into conserved cis-regulatory modules
in the promoter sequences with the Genomatix Software Suite
(Genomatix Software GmbH, Munich, Germany) [90].
4.3.2.1. Deﬁnition of the proximal promoter sequences. We used the
current human reference genome GRCh37/hg19. At ﬁrst, we selected
from the Gene2Promoter database of the Genomatix suite the best
proximal promoters (gold) associated with the transcript targeted by
the respective Affymetrix probe sets. Then, we positioned, relative to
these promoter sequences, the major TSS proposed by the NCBI and/
or UCSC databases, as well as the conﬁdent TSS given in the dbTSS
368 N. Dhaouadi et al. / Genomics 103 (2014) 357–370database [91]. The sequences of the promoters were shortened if their
3′-end contained TSS located downstream signiﬁcantly transcribed re-
gions as shown by the hybridization level of the Affymetrix probes.
For upstream conﬁdent promoters, those that were proximal were in-
cluded into the promoter sequence that never exceeded 1400 bp in
length. For conﬁdent TSS located farther upstream, alternative regulato-
ry sequences 500 bp upstream and 100 bp downstream the TSS were
designed. All the alternative promoter sequences for a given gene
were analyzed for the presence of TFBS (see below) and the one that
displayed the highest similarity with the TGFB1 promoter was chosen
and further analyzed. The selected promoter sequences and the position
of the conﬁdent TSS for TGFB1, and for the top 10 genes correlated with
TGFB1 are given in Suppl. data Part 1.
4.3.2.2. Analysis of over-representation of TFBS in the promoter sequences.
TFBS were detected with the MatInspector tool of the Genomatix Soft-
ware Suite, from PWMs generated byMatDeﬁne. In order to emphasize
the functional representation of TFBSmotifs over-represented in a set of
promoters, we used the TFBS matrix family concept. TFBS matrix fami-
lies are deﬁned as groups of TFBS weight matrices corresponding to
the same or functionally similar TFs. For any given TF, there could be
multiple matrices described by different independent sources, leading
to multiple matches for similar position or shifting of matches by a
few base pairs.
The over-representation of TFBS across the studied promoters was
tested using the CommonTFs tool of Genomatix. TFBS matrix families
aswell as individualmatrices, each corresponding to one speciﬁc factor,
were examined. The threshold for core similarity was taken at 0.75, and
for matrix similarity the optimized one was taken. Among the statisti-
cally signiﬁcant PWMs (p b 10−3), we selected those having TFBS
in the largest number of studied promoter sequences (at least 10/11,
i.e. N90%).
4.3.2.3. Analysis of transcription factormodules.Modules of TFs were in-
vestigated with the ModelInspector tool of Genomatix, selecting
those that were found in a majority of the 11 promoter sequences
examined.
4.3.3. Co-expression of transcription factors and the TGFB1 cluster
To identify TFs potentially involved in the ﬁne-tuning expression of
the studied gene cluster, the correlation between the selected TFs and
the 11 genes of the TGFB1 cluster was tested across the individual
samples of the studied group.
4.4. Statistical validation of results
4.4.1. Larger set of genes correlated with TGFB1
In order to test the robustness of the identiﬁed TFs, we performed
the same analysis of promoters on larger sets of genes correlated with
TGFB1, namely 15 and 50 genes. In the ﬁrst case the genes had correla-
tion coefﬁcient higher than 0.907, and in the second case correlation
coefﬁcient was higher than 0.880.
4.4.2. Sets of well-expressed genes not correlated with TGFB1
We analyzed sets of not co-expressed genes to test the hypothesis
that the common TFs obtained from Genomatix promoter analysis
were actually associated (causal) with the co-expression of genes.
The genes whose transcripts were not correlated with that of TGFB1
(−0.1 b r b 0.1) and had expression level close to that of genes co-
expressed with TGFB1 were derived from MIT microarray data. One
hundred random samples of 10 of these genes associated with the
TGFB1 gene made 100 random gene sets verifying the null correla-
tion hypothesis. Using Genomatix modules Gene2Promoter and
CommonTFs, the TFs having binding sites in at least 10 promoter
sequences and the number of detected TFBS were counted and
stored for further analyses.4.5. Comparison with other tissues
In all cases, the datasets were selected on two criteria: (i) TGFB1
transcript had a sufﬁcient mean level (N30th centile of the expression
distribution), and (ii) themean of the 10 highest correlation coefﬁcients
with TGFB1 transcript was greater than 0.7. The same protocol of
analysis was followed from the selection of the 10 transcripts having
the best correlation with TGFB1 transcript to the identiﬁcation of TFs
having binding sites in at least 10 of the 11 promoter sequences.
4.5.1. Atherosclerotic tissue
Firstwe analyzed data obtained in ATH samples of the samepatients.
Then public microarray data from the GEO database obtained in human
atherosclerotic carotid arterieswere analyzed (accession GSE28829 and
GSE21545).
4.5.2. Cancer tissues
Several public microarray datasets from the GEO database obtained
in 10 different types of cancer tumors were analyzed: metastatic mela-
noma (GSE30812), brain tumors (GSE16584, GSE19578), several types
of breast cancer (GSE26639, GSE36774), several stages of colon cancer
(GSE14333), liver cancer (GSE20238), lung cancer (GSE33356), and
several types of sarcoma (GSE21050).
4.6. Cell culture, treatments and quantitative RT-PCR
Primary cultures of vSMCs were obtained by the explant technique
from fragments of MIT from 6 patients not included in the series of
the 32 patients whose RNA was analyzed by microarrays. Cultures
were expanded in human vSMC culture medium (Promocell) supple-
mented with penicillin, streptomycin, fungizone and 5% fetal calf
serum in an incubator at 37 °C under a 5% CO2 atmosphere. For the ex-
periments, cells at passage 3 were grown in 6-well plates until conﬂu-
ence. From the day before treatment until the end of the experiment,
the cells were kept in mediumwithout serum. On the day of treatment,
the culture medium was changed by fresh medium containing the test
substances or the vehicle. Duplicate wells of cells from each patient
were treated for 24 h, separately or in combination, with 50, 100 and
200 nM mithramycin A (Santa Cruz Biotechnology), a SP1 inhibitor
[44], and with a PKC-ß inhibitor (CAS # 257879-35-9, Calbiochem), an
inhibitor of EGR1 activation [45]. After 24 h of treatment, the cells
were rinsed with phosphate buffer saline and total RNA was extracted
with Trizol (Invitrogen). After digestion with RNase–free DNase I
(Qiagen), total RNA was re-extracted with phenol-chloroform and
quantiﬁed. Reverse transcription was performed on 1 μg of total RNA
with Super Script II and Random Primers (Invitrogen) in a ﬁnal volume
of 25 μl. First strand cDNAs (1/25th of the reverse transcription prod-
ucts) or known amounts of the target sequences were added in dupli-
cates to the PCR reaction mix (iQ SYBR Green, Biorad) containing the
appropriate primers for TGFB1, PLXNB2, AKT1 or ENG (Suppl. Table 4)
and ampliﬁed in a MyIQ thermal cycler (Biorad). Amounts of the target
amplicons in ng were normalized by the amount of 18S rRNA in each
sample. Values in control wells were considered as 100%. A 2-way
ANOVA for repeatedmeasures followed by Bonferroni tests was applied
to compare the values of the control and treated cells. p b 0.05 was
considered as signiﬁcant.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2014.05.001.
Acknowledgments
This work was supported by the “Fondation de France” (grant no
11877) and by the French Society for Arterial Hypertension (05-
SFHTA/MSD-Chibret) for the Affymetrix experiments.
369N. Dhaouadi et al. / Genomics 103 (2014) 357–370References
[1] M.B. Eisen, P.T. Spellman, P.O. Brown, D. Botstein, Cluster analysis and display
of genome-wide expression patterns, Proc. Natl. Acad. Sci. U. S. A. 95 (1998)
14863–14868.
[2] E. Segal, M. Shapira, A. Regev, D. Pe'er, D. Botstein, D. Koller, N. Friedman, Module
networks: identifying regulatory modules and their condition-speciﬁc regulators
from gene expression data, Nat. Genet. 34 (2003) 166–176.
[3] D.J. Allocco, I.S. Kohane, A.J. Butte, Quantifying the relationship between
co-expression, co-regulation and gene function, BMC Bioinforma. 5 (2004) 18.
[4] Q. Gu, S.H. Nagaraj, N.J. Hudson, B.P. Dalrymple, A. Reverter, Genome-wide patterns
of promoter sharing and co-expression in bovine skeletal muscle, BMC Genomics 12
(2011) 23.
[5] J. Massague, TGFbeta signalling in context, Nat. Rev. Mol. Cell Biol. 13 (2012)
616–630.
[6] M.O. Li, R.A. Flavell, TGF-beta: a master of all T cell trades, Cell 134 (2008) 392–404.
[7] D.J. Grainger, Transforming growth factor beta and atherosclerosis: so far, so good
for the protective cytokine hypothesis, Arterioscler. Thromb. Vasc. Biol. 24 (2004)
399–404.
[8] D.J. Grainger, TGF-beta and atherosclerosis in man, Cardiovasc. Res. 74 (2007)
213–222.
[9] Z. Mallat, A. Gojova, C. Marchiol-Fournigault, B. Esposito, C. Kamate, R. Merval, D.
Fradelizi, A. Tedgui, Inhibition of transforming growth factor-beta signaling acceler-
ates atherosclerosis and induces an unstable plaque phenotype inmice, Circ. Res. 89
(2001) 930–934.
[10] E. Lutgens, M. Gijbels, M. Smook, P. Heeringa, P. Gotwals, V.E. Koteliansky, M.J.
Daemen, Transforming growth factor-beta mediates balance between inﬂammation
and ﬁbrosis during plaque progression, Arterioscler. Thromb. Vasc. Biol. 22 (2002)
975–982.
[11] A. Gojova, V. Brun, B. Esposito, F. Cottrez, P. Gourdy, P. Ardouin, A. Tedgui, Z. Mallat,
H. Groux, Speciﬁc abrogation of transforming growth factor-beta signaling in T cells
alters atherosclerotic lesion size and composition in mice, Blood 102 (2003)
4052–4058.
[12] A.K. Robertson, M. Rudling, X. Zhou, L. Gorelik, R.A. Flavell, G.K. Hansson, Disruption
of TGF-beta signaling in T cells accelerates atherosclerosis, J. Clin. Invest. 112 (2003)
1342–1350.
[13] A.D. Frutkin, G. Otsuka, A. Stempien-Otero, C. Sesti, L. Du, M. Jaffe, H.L. Dichek, C.J.
Pennington, D.R. Edwards, M. Nieves-Cintron, D. Minter, M. Preusch, J.H. Hu, J.C.
Marie, D.A. Dichek, TGF-{beta}1 limits plaque growth, stabilizes plaque structure,
and prevents aortic dilation in apolipoprotein E-null mice, Arterioscler. Thromb.
Vasc. Biol. 29 (2009) 1251–1257.
[14] K. Reifenberg, F. Cheng, C. Orning, J. Crain, I. Kupper, E. Wiese, M. Protschka, M.
Blessing, K.J. Lackner, M. Torzewski, Overexpression of TGF-ss1 in macrophages re-
duces and stabilizes atherosclerotic plaques in ApoE-deﬁcient mice, PLoS One 7
(2012) e40990.
[15] J. Massague, TGFbeta in Cancer, Cell 134 (2008) 215–230.
[16] E.C. Connolly, J. Freimuth, R.J. Akhurst, Complexities of TGF-beta targeted cancer
therapy, Int. J. Biol. Sci. 8 (2012) 964–978.
[17] S.J. Kim, A. Glick, M.B. Sporn, A.B.. Roberts, Characterization of the promoter region
of the human transforming growth factor-beta 1 gene, J. Biol. Chem. 264 (1989)
402–408.
[18] S.J. Kim, F. Denhez, K.Y. Kim, J.T. Holt, M.B. Sporn, A.B. Roberts, Activation of the sec-
ond promoter of the transforming growth factor-beta 1 gene by transforming
growth factor-beta 1 and phorbol ester occurs through the same target sequences,
J. Biol. Chem. 264 (1989) 19373–19378.
[19] M.C. Birchenall-Roberts, F.W. Ruscetti, J. Kasper, H.D. Lee, R. Friedman, A. Geiser, M.
B. Sporn, A.B. Roberts, S.J. Kim, Transcriptional regulation of the transforming
growth factor beta 1 promoter by v-src gene products is mediated through the
AP-1 complex, Mol. Cell. Biol. 10 (1990) 4978–4983.
[20] S.J. Kim, P. Angel, R. Lafyatis, K. Hattori, K.Y. Kim, M.B. Sporn, M. Karin, A.B. Roberts,
Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 com-
plex, Mol. Cell. Biol. 10 (1990) 1492–1497.
[21] S.J. Kim, H.D. Lee, P.D. Robbins, K. Busam, M.B. Sporn, A.B. Roberts, Regulation of
transforming growth factor beta 1 gene expression by the product of the
retinoblastoma-susceptibility gene, Proc. Natl. Acad. Sci. U. S. A. 88 (1991)
3052–3056.
[22] B.R. Dey, V.P. Sukhatme, A.B.. Roberts, M.B. Sporn, F.J. Rauscher III, S.J. Kim, Repres-
sion of the transforming growth factor-beta 1 gene by theWilms' tumor suppressor
WT1 gene product, Mol. Endocrinol. 8 (1994) 595–602.
[23] Y.D. Yoo, H. Ueda, K. Park, K.C. Flanders, Y.I. Lee, G. Jay, S.J. Kim, Regulation of
transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X
transactivator. Role in HBV pathogenesis, J. Clin. Invest. 97 (1996) 388–395.
[24] S.J. Kim, K. Park, B.B. Rudkin, B.R. Dey, M.B. Sporn, A.B. Roberts, Nerve growth factor
induces transcription of transforming growth factor-beta 1 through a speciﬁc pro-
moter element in PC12 cells, J. Biol. Chem. 269 (1994) 3739–3744.
[25] Y. Kim, V. Ratziu, S.G. Choi, A. Lalazar, G. Theiss, Q. Dang, S.J. Kim, S.L. Friedman,
Transcriptional activation of transforming growth factor beta1 and its receptors by
the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential
mechanisms for autocrine ﬁbrogenesis in response to injury, J. Biol. Chem. 273
(1998) 33750–33758.
[26] C. Weigert, K. Brodbeck, K. Klopfer, H.U. Haring, E.D. Schleicher, Angiotensin II
induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia,
Diabetologia 45 (2002) 890–898.
[27] J. Yue, K.M. Mulder, Requirement of Ras/MAPK pathway activation by transforming
growth factor beta for transforming growth factor beta 1 production in a
Smad-dependent pathway, J. Biol. Chem. 275 (2000) 30765–30773.[28] J. Shimada, Y. Suzuki, S.J. Kim, P.C. Wang, M. Matsumura, S. Kojima, Transactivation
via RAR/RXR-Sp1 interaction: characterization of binding between Sp1 and GC box
motif, Mol. Endocrinol. 15 (2001) 1677–1692.
[29] C. Weigert, K. Brodbeck, M. Sawadogo, H.U. Haring, E.D. Schleicher, Upstream
stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via
the glucose-response element-1013/-1002 in mesangial cells: up-regulation of
USF activity by the hexosamine biosynthetic pathway, J. Biol. Chem. 279 (2004)
15908–15915.
[30] K.Y. Lee, K. Ito, R. Hayashi, E.P. Jazrawi, P.J. Barnes, I.M. Adcock, NF-kappaB and acti-
vator protein 1 response elements and the role of histone modiﬁcations in IL-1beta-
induced TGF-beta1 gene transcription, J. Immunol. 176 (2006) 603–615.
[31] J.S. Mohamed, A.M. Boriek, Stretch augments TGF-beta1 expression through RhoA/
ROCK1/2, PTK, and PI3K in airway smooth muscle cells, Am. J. Physiol. Lung Cell.
Mol. Physiol. 299 (2010) L413–L424.
[32] R.L. Furler, C.H. Uittenbogaart, GLI2 regulates TGF-beta1 in human CD4+ T cells:
implications in cancer and HIV pathogenesis, PLoS One 7 (2012) e40874.
[33] M.P. Gustin, C.Z. Paultre, J. Randon, G. Bricca, C. Cerutti, Functional meta-analysis of
double connectivity in gene coexpression networks in mammals, Physiol. Genomics
34 (2008) 34–41.
[34] H.C. Stary, Natural history and histological classiﬁcation of atherosclerotic lesions:
an update, Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1177–1178.
[35] H.C. Stary, D.H. Blankenhorn, A.B. Chandler, S. Glagov,W. Insull Jr., M. Richardson, M.
E. Rosenfeld, S.A. Schaffer, C.J. Schwartz, W.D. Wagner, et al., A deﬁnition of the
intima of human arteries and of its atherosclerosis-prone regions. A report from
the Committee on Vascular Lesions of the Council on Arteriosclerosis, American
Heart Association, Arterioscler. Thromb. J. Vasc. Biol. Am. Heart Assoc. 12 (1992)
120–134.
[36] C. Fernandez-Hernando, E. Ackah, J. Yu, Y. Suarez, T. Murata, Y. Iwakiri, J.
Prendergast, R.Q. Miao, M.J. Birnbaum, W.C. Sessa, Loss of Akt1 leads to severe ath-
erosclerosis and occlusive coronary artery disease, Cell Metab. 6 (2007) 446–457.
[37] C. Fernandez-Hernando, L. Jozsef, D. Jenkins, A. Di Lorenzo, W.C. Sessa, Absence of
Akt1 reduces vascular smooth muscle cell migration and survival and induces fea-
tures of plaque vulnerability and cardiac dysfunction during atherosclerosis,
Arterioscler. Thromb. Vasc. Biol. 29 (2009) 2033–2040.
[38] A.R. Conery, Y. Cao, E.A. Thompson, C.M. Townsend Jr., T.C. Ko, K. Luo, Akt interacts
directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis, Nat.
Cell Biol. 6 (2004) 366–372.
[39] I. Remy, A. Montmarquette, S.W. Michnick, PKB/Akt modulates TGF-beta signalling
through a direct interaction with Smad3, Nat. Cell Biol. 6 (2004) 358–365.
[40] K. Song, H. Wang, T.L. Krebs, D. Danielpour, Novel roles of Akt and mTOR in sup-
pressing TGF-beta/ALK5-mediated Smad3 activation, EMBO J. 25 (2006) 58–69.
[41] N.K. Kapur, K.J. Morine, M. Letarte, Endoglin: a critical mediator of cardiovascular
health, Vasc. Health Risk Manag. 9 (2013) 195–206.
[42] J.H. Kwak, S.I. Kim, J.K. Kim, M.E. Choi, BAT3 interacts with transforming growth
factor-beta (TGF-beta) receptors and enhances TGF-beta 1-induced type I collagen
expression in mesangial cells, J. Biol. Chem. 283 (2008) 19816–19825.
[43] L.M. Botella, T. Sanchez-Elsner, F. Sanz-Rodriguez, S. Kojima, J. Shimada, M.
Guerrero-Esteo, M.P. Cooreman, V. Ratziu, C. Langa, C.P. Vary, J.R. Ramirez, S.
Friedman, C. Bernabeu, Transcriptional activation of endoglin and transforming
growth factor-beta signaling components by cooperative interaction between Sp1
and KLF6: their potential role in the response to vascular injury, Blood 100 (2002)
4001–4010.
[44] N. Osada, Y. Kosuge, K. Ishige, Y. Ito, Mithramycin, an agent for developing new
therapeutic drugs for neurodegenerative diseases, J. Pharmacol. Sci. 122 (2013)
251–256.
[45] S.F. Yan, E. Harja, M. Andrassy, T. Fujita, A.M. Schmidt, Protein kinase C beta/early
growth response-1 pathway: a key player in ischemia, atherosclerosis, and resteno-
sis, J. Am. Coll. Cardiol. 48 (2006) A47–A55.
[46] T.A. McCaffrey, C. Fu, B. Du, S. Eksinar, K.C. Kent, H. Bush Jr., K. Kreiger, T. Rosengart,
M.I. Cybulsky, E.S. Silverman, T. Collins, High-level expression of Egr-1 and Egr-1-
inducible genes in mouse and human atherosclerosis, J. Clin. Invest. 105 (2000)
653–662.
[47] T.W. Whitﬁeld, J. Wang, P.J. Collins, E.C. Partridge, S.F. Aldred, N.D. Trinklein, R.M.
Myers, Z. Weng, Functional analysis of transcription factor binding sites in human
promoters, Genome Biol. 13 (2012) R50.
[48] A. Sandelin, P. Carninci, B. Lenhard, J. Ponjavic, Y. Hayashizaki, D.A. Hume, Mammalian
RNA polymerase II core promoters: insights from genome-wide studies, Nat. Rev.
Genet. 8 (2007) 424–436.
[49] C.G. Danko, A.M. Pertsov, Identiﬁcation of gene co-regulatory modules and associat-
ed cis-elements involved in degenerative heart disease, BMC Med. Genet. 2 (2009)
31.
[50] T. Ideker, V. Thorsson, J.A. Ranish, R. Christmas, J. Buhler, J.K. Eng, R. Bumgarner, D.R.
Goodlett, R. Aebersold, L. Hood, Integrated genomic and proteomic analyses of a
systematically perturbed metabolic network, Science 292 (2001) 929–934.
[51] D. Hurley, H. Araki, Y. Tamada, B. Dunmore, D. Sanders, S. Humphreys, M. Affara, S.
Imoto, K. Yasuda, Y. Tomiyasu, K. Tashiro, C. Savoie, V. Cho, S. Smith, S. Kuhara, S.
Miyano, D.S. Charnock-Jones, E.J. Crampin, C.G. Print, Gene network inference and
visualization tools for biologists: application to new human transcriptome datasets,
Nucleic Acids Res. 40 (2012) 2377–2398.
[52] K. Basso, A.A. Margolin, G. Stolovitzky, U. Klein, R. Dalla-Favera, A. Califano, Reverse
engineering of regulatory networks in human B cells, Nat. Genet. 37 (2005)
382–390.
[53] X. Zhou, P. Sumazin, P. Rajbhandari, A. Califano, A systems biology approach to
transcription factor binding site prediction, PLoS One 5 (2010) e9878.
[54] M.S. Carro, W.K. Lim, M.J. Alvarez, R.J. Bollo, X. Zhao, E.Y. Snyder, E.P. Sulman, S.L.
Anne, F. Doetsch, H. Colman, A. Lasorella, K. Aldape, A. Califano, A. Iavarone, The
370 N. Dhaouadi et al. / Genomics 103 (2014) 357–370transcriptional network for mesenchymal transformation of brain tumours, Nature
463 (2010) 318–325.
[55] S.J. Devlin, R. Gnanadesikan, J.R. Kettenring, Robust estimation and outlier detection
with correlation coefﬁcients, Biometrika 62 (1975) 531–545.
[56] J.C. Sluimer, N. Kisters, K.B. Cleutjens, O.L. Volger, A.J. Horrevoets, L.H. van den Akker,
A.P. Bijnens, M.J. Daemen, Dead or alive: gene expression proﬁles of advanced
atherosclerotic plaques from autopsy and surgery, Physiol. Genomics 30 (2007)
335–341.
[57] C. Weigert, U. Sauer, K. Brodbeck, A. Pfeiffer, H.U. Haring, E.D. Schleicher, AP-1 pro-
teins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter
in mesangial cells, J. Am. Soc. Nephrol. 11 (2000) 2007–2016.
[58] S. Bhattacharyya, F. Fang, W. Tourtellotte, J. Varga, Egr-1: new conductor for the
tissue repair orchestra directs harmony (regeneration) or cacophony (ﬁbrosis), J.
Pathol. 229 (2013) 286–297.
[59] N.Y. Tan, L.M. Khachigian, Sp1 phosphorylation and its regulation of gene transcrip-
tion, Mol. Cell. Biol. 29 (2009) 2483–2488.
[60] C. Liu, E. Adamson, D. Mercola, Transcription factor EGR-1 suppresses the growth and
transformation of human HT-1080 ﬁbrosarcoma cells by induction of transforming
growth factor beta 1, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11831–11836.
[61] K. Yasuda, K. Hirayoshi, H. Hirata, H. Kubota, N. Hosokawa, K. Nagata, The
Kruppel-like factor Zf9 and proteins in the Sp1 family regulate the expression
of HSP47, a collagen-speciﬁc molecular chaperone, J. Biol. Chem. 277 (2002)
44613–44622.
[62] N. Bhaskaran, S. Souchelnytskyi, Systemic analysis of TGFbeta proteomics revealed
involvement of Plag1/CNK1/RASSF1A/Src network in TGFbeta1-dependent activa-
tion of Erk1/2 and cell proliferation, Proteomics 8 (2008) 4507–4520.
[63] R. Zhao, L. Gong, L. Li, L. Guo, D. Zhu, Z.Wu, Q. Zhou, nm23-H1 is a negative regulator
of TGF-beta1-dependent induction of epithelial–mesenchymal transition, Exp. Cell
Res. 319 (2013) 740–749.
[64] H.A. Seong, H. Jung, H. Ha, NM23-H1 tumor suppressor physically interacts with
serine–threonine kinase receptor-associated protein, a transforming growth
factor-beta (TGF-beta) receptor-interacting protein, and negatively regulates
TGF-beta signaling, J. Biol. Chem. 282 (2007) 12075–12096.
[65] R. Bergstrom, K. Savary, A. Moren, S. Guibert, C.H. Heldin, R. Ohlsson, A. Moustakas,
Transforming growth factor beta promotes complexes between Smad proteins and
the CCCTC-binding factor on the H19 imprinting control region chromatin, J. Biol.
Chem. 285 (2010) 19727–19737.
[66] J.H. Cho, M.J. Kim, K.J. Kim, J.R. Kim, POZ/BTB and AT-hook-containing zinc ﬁnger
protein 1 (PATZ1) inhibits endothelial cell senescence through a p53 dependent
pathway, Cell Death Differ. 19 (2012) 703–712.
[67] Y. Lu, S. Haldar, K. Croce, Y. Wang, M. Sakuma, T. Morooka, B. Wang, D. Jeyaraj, S.J.
Gray, D.I. Simon, M.K. Jain, Kruppel-like factor 15 regulates smooth muscle response
to vascular injury—brief report, Arterioscler. Thromb. Vasc. Biol. 30 (2010)
1550–1552.
[68] S.M. Haldar, Y. Lu, D. Jeyaraj, D. Kawanami, Y. Cui, S.J. Eapen, C. Hao, Y. Li, Y.Q.
Doughman, M. Watanabe, K. Shimizu, H. Kuivaniemi, J. Sadoshima, K.B. Margulies,
T.P. Cappola, M.K. Jain, Klf15 deﬁciency is a molecular link between heart failure
and aortic aneurysm formation, Sci. Transl. Med. 2 (2010) 26ra26.
[69] D.K. Lee, D. Suh, H.J. Edenberg, M.W. Hur, POZ domain transcription factor, FBI-1,
represses transcription of ADH5/FDH by interacting with the zinc ﬁnger and inter-
fering with DNA binding activity of Sp1, J. Biol. Chem. 277 (2002) 26761–26768.
[70] T. Sakai, K. Hino, S. Wada, H. Maeda, Identiﬁcation of the DNA binding speciﬁcity of
the human ZNF219 protein and its function as a transcriptional repressor, DNA Res.
10 (2003) 155–165.
[71] V. Andreoli, R.C. Gehrau, J.L. Bocco, Biology of Kruppel-like factor 6 transcriptional
regulator in cell life and death, IUBMB Life 62 (2010) 896–905.
[72] L.M. Botella, F. Sanz-Rodriguez, Y. Komi, L.A. Fernandez, E. Varela, E.M. Garrido-
Martin, G. Narla, S.L. Friedman, S. Kojima, TGF-beta regulates the expression of
transcription factor KLF6 and its splice variants and promotes co-operative
transactivation of common target genes through a Smad3-Sp1-KLF6 interaction,
Biochem. J. 419 (2009) 485–495.[73] D.P. Sparling, B.A. Griesel, J. Weems, A.L. Olson, GLUT4 enhancer factor (GEF) inter-
acts with MEF2A and HDAC5 to regulate the GLUT4 promoter in adipocytes, J. Biol.
Chem. 283 (2008) 7429–7437.
[74] Y.C. Chen, S.D. Lee, C.H. Kuo, L.T. Ho, The effects of altitude training on the AMPK-
related glucose transport pathway in the red skeletal muscle of both lean and
obese Zucker rats, High Alt. Med. Biol. 12 (2011) 371–378.
[75] J.C. Sluimer, J.M. Gasc, J.L. van Wanroij, N. Kisters, M. Groeneweg, M.D. Sollewijn
Gelpke, J.P. Cleutjens, L.H. van den Akker, P. Corvol, B.G. Wouters, M.J. Daemen, A.
P. Bijnens, Hypoxia, hypoxia-inducible transcription factor, and macrophages in
human atherosclerotic plaques are correlated with intraplaque angiogenesis, J.
Am. Coll. Cardiol. 51 (2008) 1258–1265.
[76] B.K. Lee, A.A. Bhinge, V.R. Iyer, Wide-ranging functions of E2F4 in transcriptional ac-
tivation and repression revealed by genome-wide analysis, Nucleic Acids Res. 39
(2011) 3558–3573.
[77] C.R. Chen, Y. Kang, P.M. Siegel, J. Massague, E2F4/5 and p107 as Smad cofactors
linking the TGFbeta receptor to c-myc repression, Cell 110 (2002) 19–32.
[78] P.H. Giangrande, J. Zhang, A. Tanner, A.D. Eckhart, R.E. Rempel, E.R. Andrechek, J.M.
Layzer, J.R. Keys, P.O. Hagen, J.R. Nevins, W.J. Koch, B.A. Sullenger, Distinct roles of
E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia,
Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12988–12993.
[79] A. Cheong, I.C.Wood, D.J. Beech, Less REST, more vascular disease? Regulation of cell
cycle and migration of vascular smooth muscle cells, Cell Cycle 5 (2006) 129–131.
[80] B.K. Ray, A. Shakya, J.R. Turk, S.S. Apte, A. Ray, Induction of the MMP-14 gene in
macrophages of the atherosclerotic plaque: role of SAF-1 in the induction process,
Circ. Res. 95 (2004) 1082–1090.
[81] S. Kumar, C.C. Pan, J.C. Bloodworth, A. Nixon, C. Theuer, D.G. Hoyt, N.Y. Lee,
Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for
endoglin shedding and deregulation of TGF-beta signaling, Oncogene (2013),
http://dx.doi.org/10.1038/onc.2013.386 [Epub ahead of print].
[82] J.P. Maloney, R.S. Stearman, T.M. Bull, D.W. Calabrese, M.L. Tripp-Addison, M.J. Wick,
U. Broeckel, I.M. Robbins, L.A. Wheeler, J.D. Cogan, J.E. Loyd, Loss-of-function
thrombospondin-1 mutations in familial pulmonary hypertension, Am. J. Physiol.
Lung Cell. Mol. Physiol. 302 (2012) L541–L554.
[83] S. Frietze, X. Lan, V.X. Jin, P.J. Farnham, Genomic targets of the KRAB and SCAN
domain-containing zinc ﬁnger protein 263, J. Biol. Chem. 285 (2010) 1393–1403.
[84] K. Aurrekoetxea-Hernandez, E. Buetti, Transforming growth factor beta enhances
the glucocorticoid response of the mouse mammary tumor virus promoter through
Smad and GA-binding proteins, J. Virol. 78 (2004) 2201–2211.
[85] M.F. Crook, M. Olive, H.H. Xue, T.H. Langenickel, M. Boehm, W.J. Leonard, E.G. Nabel,
GA-binding protein regulates KIS gene expression, cell migration, and cell cycle
progression, FASEB J. 22 (2008) 225–235.
[86] C.K. Sung, J. Dahl, H. Yim, S. Rodig, T.L. Benjamin, Transcriptional and post-
translational regulation of the quiescence factor and putative tumor suppressor
p150(Sal2), FASEB J. 25 (2011) 1275–1283.
[87] C.L. Vrins, R. Out, P. van Santbrink, A. van der Zee, T. Mahmoudi, M. Groenendijk, L.
M. Havekes, T.J. van Berkel, K. Willems van Dijk, E.A. Biessen, Znf202 affects high
density lipoprotein cholesterol levels and promotes hepatosteatosis in hyperlipid-
emic mice, PLoS One 8 (2013) e57492.
[88] M.C. Stene, R. Frikke-Schmidt, B.G. Nordestgaard, P. Grande, P. Schnohr, A. Tybjaerg-
Hansen, Functional promoter variant in zinc ﬁnger protein 202 predicts severe
atherosclerosis and ischemic heart disease, J. Am. Coll. Cardiol. 52 (2008) 369–377.
[89] World Medical Association Declaration of Helsinki, Recommendations guiding
physicians in biomedical research involving human subjects, Cardiovasc. Res. 35
(1997) 2–3.
[90] K. Cartharius, K. Frech, K. Grote, B. Klocke, M. Haltmeier, A. Klingenhoff, M. Frisch, M.
Bayerlein, T. Werner, MatInspector and beyond: promoter analysis based on
transcription factor binding sites, Bioinformatics 21 (2005) 2933–2942.
[91] R. Yamashita, N.P. Sathira, A. Kanai, K. Tanimoto, T. Arauchi, Y. Tanaka, S. Hashimoto,
S. Sugano, K. Nakai, Y. Suzuki, Genome-wide characterization of transcriptional start
sites in humans by integrative transcriptome analysis, Genome Res. 21 (2011)
775–789.
